- Intellectual Property (14)
- Litigation / Dispute Resolution (14)
- Healthcare (13)
- Company/Commercial (11)
- Corporate (9)
- Information Technology (8)
- Regulatory and compliance (7)
- Banking / Finance (5)
- Clinical/Medical Negligence (4)
- Employment (4)
- Commodities (3)
- Real Estate (3)
- Competition/EU (2)
- Crime (2)
- Energy (2)
- Insurance/reinsurance (2)
- Media/Entertainment/Sport (2)
- Privacy and reputation (2)
- Private Equity (2)
- Tax (2)
- Agriculture (1)
- Environment (1)
- Financial services (1)
- Funds (1)
- Licensing/Gaming/Betting (1)
- Public Sector/Local Authority (1)
- Telecoms (1)
Sort By: Newest first | Oldest first
Debates on the laws and regulations that will govern biosimilar products have been raging for some time.
Intellectual Property and Technology News — state biosimilars laws are evolving; surviving a trademark opposition challenge; and more
DLA Piper has released issue 23 of its Intellectual Property and Technology News, which reports on worldwide developments in IP and technology law.
Life Sciences Spotlight: Chinese regulatory enforcement action not slowing down; patent strategies and loyalty discounts; and more
DLA Piper has released the fourth edition of Life Sciences Spotlight, which discusses developments in the sector across the Asia-Pacific region.
Life Sciences Spotlight: Chinese regulatory enforcement action showing no signs of slowing down; and more
Welcome to the fourth edition of Life Sciences Spotlight.
European Commission fines Servier and five generic companies for curbing entry of cheaper versions of cardiovascular medicine
The European Commission has imposed fines totalling €427.7m on the French pharmaceutical company Servier and five producers of generic medicines.
DLA Piper has announced that Shane Albright has joined the firm’s corporate and finance practice as a partner in the Silicon Valley office.
Antitrust and competition enforcement is changing fast: our report for multinationals from three global conferences
The world of antitrust/competition enforcement is changing more rapidly than ever. This evolving environment presents new challenges for companies.
Amy Jensen Cunniffe has joined DLA Piper’s government affairs and healthcare public policy and regulatory practices as a senior policy adviser in Washington DC.
DLA Piper has advised Parnell Pharmaceuticals Holdings (PARN) in its initial public offering on NASDAQ.
DLA Piper has announced that Ben Boyd and Mary Gately have been named co-managing partners of the Washington DC office.
In food marketing litigation, class certification is a major hurdle for would-be class plaintiffs, but a recent case may have lowered the bar with a flexible approach to class certification.
DLA Piper has announced that Lisa Haile and Mark Fowler have been named to the Daily Journal’s 2014 list of ‘Top Intellectual Property Lawyers’.
DLA Piper has secured the dismissal of patent infringement claims against subsidiaries of St Jude Medical, a global medical device manufacturer, by Volcano Corp.
California GCI’s coming priority products list and the DTSC Strategic Plan — what do they mean for you?
The highly anticipated next step in California’s Green Chemistry Initiative (GCI) is the planned April 2014 release of the list of ‘priority products’.
DLA Piper has released the 3 February 2014 issue of its Health Alert, which focuses on judgments, legislation and reports in the health sector.
DLA Piper has released the 28 January 2014 issue of its Health Alert, which focuses on judgments, legislation and reports in the health sector.
DLA Piper has represented Arsenal Capital Partners in its purchase of Certara, a biopharmaceutical service provider.
DLA Piper advised on more than 20 significant inbound and outbound US transactions that closed last year on behalf of Israeli institutional investors and companies.
DLA Piper has announced that Wayne P Bunch Jr has joined the law firm’s franchise and distribution practice as a partner in the Houston office.
The Australian High Court has delivered its first judgment that directly considers the patentability of methods of medical treatment.